These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 12615426

  • 1. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
    Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML.
    Vaccine; 2003 Mar 28; 21(13-14):1317-26. PubMed ID: 12615426
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML.
    Vaccine; 2006 Jan 16; 24(3):304-16. PubMed ID: 16125282
    [Abstract] [Full Text] [Related]

  • 3. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS, Morrison SL, Penichet ML.
    Vaccine; 2005 Sep 15; 23(39):4793-803. PubMed ID: 15967544
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML.
    J Immunol; 2000 Nov 01; 165(9):5112-21. PubMed ID: 11046042
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N, Hashemi SM, Hassan ZM.
    Cell Stress Chaperones; 2011 Jan 01; 16(1):41-8. PubMed ID: 20730610
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
    Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U.
    BMC Cancer; 2017 Feb 09; 17(1):118. PubMed ID: 28183282
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y, Wu J, Xu A, Ahmeqd S, Sami A, Chibbar R, Freywald A, Zheng C, Xiang J.
    Vaccine; 2018 Mar 07; 36(11):1414-1422. PubMed ID: 29415817
    [Abstract] [Full Text] [Related]

  • 16. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB.
    Breast Cancer Res; 2005 Mar 07; 7(5):R580-8. PubMed ID: 16168101
    [Abstract] [Full Text] [Related]

  • 17. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
    Penichet ML, Dela Cruz JS, Shin SU, Morrison SL.
    Hum Antibodies; 2001 Mar 07; 10(1):43-9. PubMed ID: 11455061
    [Abstract] [Full Text] [Related]

  • 18. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.
    J Immunol; 2003 Oct 15; 171(8):4054-61. PubMed ID: 14530326
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
    Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet ML, Montano RF.
    Mol Cancer Ther; 2010 Aug 15; 9(8):2175-85. PubMed ID: 20682652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.